Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults With Erythropoietic Protoporphyria

NCT06971900 is registered in ClinicalTrials.gov with Portal Therapeutics, Inc. as lead sponsor.

NCT NCT06971900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06971900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults With Erythropoietic Protoporphyria
Lead sponsor
Portal Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 4, 2025
Completion date
November 24, 2025
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erythropoietic protoporphyria (epp)